Authors: L. Nepovímová 1,2; P. Prášil 1,2; R. Kukla 3,4 Authors‘ workplace: Klinika infekčních nemocí, Fakultní nemocnice Hradec Králové 1; Klinika infekčních nemocí, Univerzita Karlova, Lékařská fakulta v Hradci Králové 2; Ústav klinické mikrobiologie, Fakultní nemocnice Hradec Králové 3; Ústav klinické mikrobiologie, Univerzita Karlova, Lékařská fakulta v Hradci Králové 4 Published in: Epidemiol. Mikrobiol. Imunol. 75, 2026, č. 1, s. 15-23 Category: Original Papers doi: https://doi.org/10.61568/emi/11-6659/20260202/142616
Objective: To establish the correct diagnosis of the disease. To interpret the results of semi-quantitative viraemia testing. To evaluate the clinical and laboratory course of the disease.
Material and methods: At the Department of Infectious Diseases of the University Hospital of Hradec Králové and the Faculty of Medicine of Charles University, patients (n = 18) with parvovirus B19 infection were retrospectively studied for the period from March 1 to June 30, 2024. Their clinical condition, viraemia levels, and routine laboratory haematological and biochemical data were monitored.
Results: Viraemia levels ranged from 105 to 1011 copies/ml. Levels below 107 copies/ml were detected in patients with symptoms persisting for more than a week or considered as complications of the infection. In addition to exanthema and fever, the clinical course was characterised by pharyngitis, headache, vomiting in young children, arthralgia in adults, and, surprisingly, abdominal pain, meningism, hepatopathy with conjugated hyperbilirubinemia, and anaemic syndrome. Most adult patients had leukopenia, some with concomitant thrombocytopenia, but always with spontaneous resolution within eight days without complications. Such changes in blood counts were not observed in paediatric patients.
Conclusion: To diagnose parvovirus B19 infection, it is important to know the possible clinical courses and typical laboratory findings, to have access to rapid PCR testing with quantitative viraemia values, and to be able to interpret these data. We consider viraemia levels of 10⁷ copies/ml and above within a week of the onset of symptoms to confirm the diagnosis. Lower values need to be interpreted with caution. Based on the duration of symptoms and clinical course, we can consider an immunopathological reaction caused by parvovirus B19 or an incidental finding of viraemia in another diagnosis, especially when there is a high circulation of the virus in the population.
parvovirus B19 – viraemia – megalerythema infectiosum
1. Mossong J, Hens N, Friederichs V., et al. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiology & Infection. 2008;136(8):1059–1068. DOI: 10.1017/S0950268807009661.
2. Young NS, Brown KE. Parvovirus B19. New England Journal of Medicine. 2004;350(6): 586–597. DOI: 10.1056/NEJMra030840.
3. Increased Parvovirus B19 activity in Europe, ECDC emphasises enhanced awareness for vulnerable populations [online]. 2024 - 05-06. Dostupný na www: https://www.ecdc.europa.eu/en/ news-events/increased-parvovirus-b19-activity-europe-ecdc - -emphasises-enhanced-awareness-vulnerable.
4. Brown KE. Human Parvoviruses including parvovirus B19 and human bocaparvoviruses. In: Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett‘s Principles and Practice of Infectious Diseases. 9th ed. Volume 1–2. Philadelphia: Elsevier; 2019 : 1969–1975. ISBN - 13 : 978-0323482554.
5. Pinho JRR, Alves VAF, Vieira AF, et al. Detection of human parvovirus B19 in a patient with hepatitis. Brazilian Journal of Medical and Biological Research. 2001;34 : 1131–1138. DOI: 10.1590/ s0100-879x2001000900005.
6. Hatakka A, Klein J, He R, et al. Acute hepatitis as a manifestation of parvovirus B19 infection. Journal of Clinical Microbiology. 2011;49(9):3422–3424. DOI: 10.1128/JCM.00575-11.
7. Watzinger D, Suda M, Preuner S, et al. Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. Journal of Clinical Microbiology. 2004;42(11):5189–5198. DOI: 10.1128/ JCM.42.11.5189-5198.2004.
8. Guillet M, Bas A, Lacoste M, et al. New atypical epidemiological profile of parvovirus B19 revealed by molecular screening of blood donations, France, winter 2023/ 24. Eurosurveillance, 2024;29(21).
9. Tóth F, Moser T, Boros Á, et al. Seroepidemiology (2018–2024) and epidemic spread of an emerging human parvovirus B19 genotype 1 (subtype 1a2) variant in Hungary, 2023/2024. Arch Virol., 2025;170(2):45. DOI: 10.1007/s00705-025-06228-2.
10. Hübschen JM, Mihneva Z, Mentis AF, et al. Phylogenetic analysis of human parvovirus B19 sequences from eleven different countries confirms the predominance of genotype 1 and suggests the spread of genotype 3b. Journal of clinical mikrobiology, 2009;47(11):3735–3738. DOI: 10.1128/JCM.01201-09.
11. Takano T, Yamada K. Quantitation of human parvovirus B19 DNA by real‐time polymerase chain reaction. Pediatrics International. 2007;49(4):459–462. DOI: 10.1111/j.1442-200X.2007.02388.x.
12. Dittmer FP, Guirmarães CM, Peixoto A, et al. Parvovirus B19 Infection and Pregnancy: Review of the Current Knowledge, J Pers Med. 2024;14(2):139. DOI: 10.3390/jpm14020139.
13. Alfego D. Detection of increased activity of human parvovirus B19 using commercial laboratory testing of clinical samples and source plasma donor pools — United States. MMWR. Morbidity and Mortality Weekly Report., 2024;73(47):1076–1081. DOI: 10.15585/mmwr.mm7347a2.
14. Kooistra K, Mesman HJ, De Waal M, et al. Epidemiology of high ‐ level parvovirus B19 viraemia among Dutch blood donors, 2003–2009. Vox sanguinis. 2011;100(3):261–266. DOI: 10.1111/j. 1423-0410.2010.01423.x.
15. Kleinman SH, Glynn SA, Lee TH, et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion, 2007;47(10):1756–1764. DOI: 10.1111/j. 1537-2995.2007.01341.x.
16. Shin H, Park S, Lee GW, et al. Parvovirus B19 infection presenting with neutropenia and thrombocytopenia: Three case reports. Medicine, 2019;98(35), e16993. DOI: 10.1097/ MD.0000000000016993.
17. Hayakawa H, Tara M, Niina K, et al. A clinical study of adult human parvovirus B19 infection. Internal medicine, 2002;41(4):295–299. DOI: 10.2169/internalmedicine.41.295.
18. Herzog-Tzarfati K, Shiloah E, Koren-Michowitz M, et al. Successful treatment of prolonged agranulocytosis caused by acute parvovirus B19 infection with intravenous immunoglobulins. European Journal of Internal Medicine, 2006;17(6): 439–440. DOI: 10.1016/j.ejim.2006.02.014.
19. Kobayashi Y, Hatta Y, Ishiwatari Y, et al. Human parvovirus B19-induced aplastic crisis in an adult patient with hereditary spherocytosis: a case report and review of the literature. BMC Research Notes, 2014;7 : 1–5. DOI: 10.1186/1756-0500-7-137.
20. Crane J, Mundle W, Boucoiran I. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 2014;36(12):1107–1116. DOI: 10.1016/S1701-2163(15)30390-X.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
